

SOTI and TROPOS phase III studies open-label extension. The long term efficacy and long term safety assessment of a five-year oral administration of strontium ranelate in osteoporotic postmenopausal women having participated either in Spinal Osteoporosis Therapeutic Intervention "SOTI" study or TReatment Of Peripheral OSteoporosis "TROPOS" study. A five-year multicentric multinational open study with strontium ranelate.

Submission date 05/09/2007	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 16/05/2008	Overall study status Completed	☐ Statistical analysis plan
		☒ Results
Last Edited 18/04/2018	Condition category Musculoskeletal Diseases	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)
Scientific

Contact name
Prof J Y Reginster

Contact details
Unité d'Exploration du Métabolisme Osseux
CHU BRULL

45, Quai Godefroid Kurth
Liege
Belgium
4020

Additional identifiers

Protocol serial number

CL3-12911-012

Study information

Scientific Title

SOTI and TROPOS phase III studies open-label extension. The long term efficacy and long term safety assessment of a five-year oral administration of strontium ranelate in osteoporotic postmenopausal women having participated either in Spinal Osteoporosis Therapeutic Intervention "SOTI" study or TReatment Of Peripheral Osteoporosis "TROPOS" study. A five-year multicentric multinational open study with strontium ranelate.

Study objectives

1. To assess the efficacy of an additional 5-year oral administration of strontium ranelate on bone mineral density (BMD), on the number of patients experiencing new osteoporotic fractures on body height and on bone markers in the SOTI and TROPOS patients having already received active treatment for 4 or 5 years
2. To allow patients treated with placebo in the main part of the SOTI study or for 5 years in the TROPOS study to receive active treatment for a duration known to be effective on vertebral fractures
3. To assess the safety of an additional 5-year oral administration of strontium ranelate in SOTI and TROPOS patients having already received active treatment for 4 or 5 years
4. To assess the safety of a 5-year oral administration of strontium ranelate in SOTI and TROPOS patients treated with placebo in the main part of the SOTI or TROPOS studies

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Primary study design

Interventional

Study design

Open international multicentric study

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Postmenopausal osteoporosis

Interventions

All participants will take 2 g per day of strontium ranelate for five years.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Strontium ranelate

Primary outcome(s)

The following will be assessed annually during the treatment:

1. Dual X-ray absorptiometry (DXA)
2. Vertebral fractures radiographs in patients having had vertebral radiographs in SOTI or TROPOS
3. Occurrence of peripheral fractures

Key secondary outcome(s)

Safety

Completion date

31/12/2009

Eligibility**Key inclusion criteria**

1. Caucasian women
2. Postmenopausal
3. Osteoporosis
4. Having participated up to the SOTI or TROPOS M060 visit or withdrawn under study treatment from the SOTI or TROPOS study within a 6-month period preceding the theoretical M060 visit

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. Patients having attended the M060 or withdrawn SOTI-TROPOS visit at a time greater than one year prior to the inclusion visit of the CL3-12911-012 protocol
2. Significant concomitant disease (evolutive major illnesses)
3. Severe disease interfering with bone metabolism

Date of first enrolment

09/09/2002

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

United Kingdom

Australia

Belgium

Denmark

France

Germany

Hungary

Italy

Poland

Spain

Switzerland

Study participating centre

Unité d'Exploration du Métabolisme Osseux

Liege

Belgium

4020

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

ROR

<https://ror.org/034e7c066>

Funder(s)

Funder type

Industry

Funder Name

Institut de Recherches Internationales Servier (France)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com/> if a Marketing Authorisation has been granted after 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2012		Yes	No
Basic results				No	No